Barrington Research has acted as Co-Manager in a $81,812,500 underwritten public offering of common stock for AtriCure, Inc. (ATRC-NASDAQ).
CHICAGO, June 5, 2014 — Barrington Research Associates, Inc. (www.brai.com), a nationally recognized investment services firm, has acted as Co-Manager in a $81,812,500 underwritten public offering of common stock for AtriCure, Inc. (ATRC-NASDAQ).
The offering consisted of 4,250,000 shares of its common stock offered to the public priced at $19.25 per share and includes an overallotment option up to an additional 637,500 shares of common stock. The transaction was priced on February 14, 2014 and closed on February 19, 2014.
Piper Jaffray & Co. acted as sole book-running manager in the offering. Co-Manager’s included Barrington Research Associates, Canaccord Genuity, Leerink, and Stifel.
The offering was made pursuant to a shelf registration statement (File No. 333-193370) previously filed with and declared effective by the U.S. Securities and Exchange Commission (SEC).
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Any offer, solicitation or sale will be made only by means of the prospectus supplement and the base prospectus.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.